They say take a breath Pharmaceutical companies how will they get with his raise state budget on medicines for 200 million euros, as they believe that part of the involuntary reimbursements they pay to the state will be reduced (discount, return) and are a “splinter” for their income.

Budget increases of 50 million euros for 2022 and 150 million euros for 2023 in the individual expenditure budgets for community pharmacies. EOPYYhigh-cost medicines and hospitals, in fact, meet the objectives of reducing the QB, that is, the amount that pharmaceutical companies are required to pay in case of exceeding the budget for pharmaceutical spending.

These targets, defined by the country’s commitment to the Recovery Fund, do not seem to be achievable, as market leaders report that spending on medicines is constantly rising. Due to the possible failure to meet the targets, the state will have to cover the costs, which will result in an additional 200 million euros for strengthening the budget. “It’s certainly a breather, but with pharmaceutical costs rising every year, I’m afraid there’s a hole in the water.” tells “K” a high-ranking head of the pharmaceutical industry. It is noted that the pharmaceutical budget for covering the needs of patients by the state is approximately 2.5 billion euros (2 billion euros for out-of-hospital expenses, 528 million euros for hospital expenses).

The GPA was recently published to allocate an additional 50 million euros and 150 million euros, which is expected to replenish the drug budget. After intensive consultations by the Minister of Health with representatives of PEF and SFEE – multinational corporations requested the support of HYKs (expensive medicines) and hospitals, given that they are burdened with a large number of returns – it was decided in general for 2022 and 2023 their distribution as follows: 75 million euros for EOPYY community pharmacies, 65 million euros for the pharmaceutical costs of FYK pharmacies of EOPYY and 60 million euros to strengthen the hospital pharmaceutical costs of ESY hospitals. Market leaders believe hospital spending on pharmaceuticals should be increased given that they are the most compensated. The total reimbursement companies have to bear for hospital drugs could be as high as 70% of total costs, they said.